In these and/or other clinical trials in patients with gastric cancer receiving cytotoxic chemotherapy, it might also be of particular interest to try to define precisely the impact of correcting anaemia with erythropoietin in terms of quality of life and therapeutic outcome. This evidence concerns the gene EPO and anemia (phenotype).